UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM 8-K
 
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported) March 23, 2005
 
 
 NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
001-32177
 
22-2407152
(State or other jurisdiction
of incorporation)
 
(Commission File No.)
 
(I.R.S. Employer
Identification No.)
 
25 Minneakoning Road
Flemington, New Jersey 08822
(Address of principal executive offices) (Zip Code)
 
(908) 782-3431
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 7.01. Regulation FD Disclosure.

On March 23, 2005 NovaDel Pharma Inc. (the “Company”) issued a press release to announce that the Company would present at the Micro-Cap Investor’s Summit on March 24, 2005, in New York City.  The Company hereby incorporates by reference herein the information set forth in the slide presentation to be presented at the forum, a copy of which is attached hereto as Exhibit 99.1. The full text of the press release is set forth in Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.
 
99.1  
Slide Presentation used at March 24, 2005 Micro-Cap Investor’s Summit.
99.2  
Press release dated March 23, 2005, titled “NovaDel Pharma Inc. to Present at the Micro-Cap Investor’s Summit.”
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  NovaDel Pharma Inc.
 
 		  
 		  
 
By:   /s/ Jean W. Frydman
 
Name: Jean W. Frydman
 
Title: Vice President, General Counsel
and Corporate Secretary
 
Date: March 28, 2005